What are the dopamine D2, histamine H1, and anticholinergic (muscarinic) activities of droperidol and haloperidol (Haldol)?

Receptor Activity Profile of Droperidol and Haloperidol

Both droperidol and haloperidol are butyrophenone antipsychotics with strong dopamine D2 receptor antagonism, but they differ significantly in their histamine H1 and anticholinergic (muscarinic) activities. 1

Dopamine D2 Receptor Activity

Haloperidol (Haldol)

• Strong D2 antagonist - this is its primary mechanism of action as a typical antipsychotic 2
• Achieves 50% D2 occupancy at plasma levels of 0.51 ng/ml and 80% occupancy at 2.0 ng/ml 3
• D2 receptor blockade is the primary mechanism responsible for both therapeutic effects and extrapyramidal side effects 4

Droperidol

• Strong D2 antagonist - also a butyrophenone with potent dopaminergic blockade 5
• Acts centrally by occupying GABA receptors on postsynaptic membranes in addition to D2 blockade 6
• More rapid onset of sedation compared to haloperidol (3-10 minutes) 7, 8

Histamine H1 Receptor Activity

Neither droperidol nor haloperidol has significant H1 antihistamine activity. These are not antihistaminic agents - they are pure antipsychotics without the sedating antihistamine properties seen in drugs like promethazine or diphenhydramine.

The evidence clearly distinguishes these butyrophenones from phenothiazines with antihistamine properties. When the guidelines discuss H1 antagonism, they reference promethazine (a phenothiazine), not droperidol or haloperidol 6.

Anticholinergic (Muscarinic) Activity

Haloperidol

• Minimal to low anticholinergic activity 9
• As a high-potency typical antipsychotic, haloperidol produces more extrapyramidal symptoms rather than anticholinergic effects 9
• Some research suggests haloperidol can interact with muscarinic M1 receptors in vitro, but this is not clinically significant anticholinergic activity 10

Droperidol

• Minimal anticholinergic activity 6
• Like haloperidol, droperidol is not known for anticholinergic side effects
• The evidence does not support clinically relevant muscarinic receptor antagonism

Clinical Implications

The key distinction is that low-potency antipsychotics (like chlorpromazine and thioridazine) have significant anticholinergic effects including sedation and memory deficits, while high-potency agents like haloperidol and droperidol produce extrapyramidal symptoms instead 9. This is why anticholinergic agents are often added to treat drug-induced Parkinsonism from these medications 1.

Important Safety Considerations

Both drugs carry FDA black box warnings for QTc prolongation, though subsequent evidence suggests the actual cardiac risk may be lower than initially feared 1, 11:

• Haloperidol: 7 ms mean QT prolongation 1
• Both can cause extrapyramidal symptoms including acute dystonia, akathisia, and drug-induced Parkinsonism 1

Droperidol demonstrates faster onset and more effective sedation than haloperidol for acute agitation, requiring fewer repeat doses 7, 8.